E
AVITA Medical, Inc.
AVHHL
$1.65
$0.2316.20%
E
Sell
2/18/2025Downgrade
AVITA Medical, Inc. (AVHHL) was downgraded to E+ from D- on 2/18/2025 due to a noticeable decline in the solvency index, total return index and valuation index. Debt to equity increased from 3.48 to 9.59, and the quick ratio declined from 3.21 to 2.37.
AVITA Medical, Inc. (AVHHL) was downgraded to E+ from D- on 2/18/2025 due to a noticeable decline in the solvency index, total return index and valuation index. Debt to equity increased from 3.48 to 9.59, and the quick ratio declined from 3.21 to 2.37.
D
Sell
1/21/2025Upgraded
AVITA Medical, Inc. (AVHHL) was upgraded to D- from E+ on 1/21/2025 due to an increase in the valuation index and total return index.
AVITA Medical, Inc. (AVHHL) was upgraded to D- from E+ on 1/21/2025 due to an increase in the valuation index and total return index.
E
Sell
12/2/2024Downgrade
AVITA Medical, Inc. (AVHHL) was downgraded to E+ from D- on 12/2/2024 due to a significant decline in the solvency index, growth index and valuation index. Debt to equity increased from 1.75 to 3.48, the quick ratio declined from 4.65 to 3.21, and earnings per share declined from -$0.5975 to -$0.6237.
AVITA Medical, Inc. (AVHHL) was downgraded to E+ from D- on 12/2/2024 due to a significant decline in the solvency index, growth index and valuation index. Debt to equity increased from 1.75 to 3.48, the quick ratio declined from 4.65 to 3.21, and earnings per share declined from -$0.5975 to -$0.6237.
D
Sell
10/20/2023Upgraded
AVITA Medical, Inc. (AVHHL) was upgraded to D- from E+ on 10/20/2023 due to a noticeable increase in the valuation index, solvency index and growth index. Total revenue increased 11.4% from $10.55M to $11.75M.
AVITA Medical, Inc. (AVHHL) was upgraded to D- from E+ on 10/20/2023 due to a noticeable increase in the valuation index, solvency index and growth index. Total revenue increased 11.4% from $10.55M to $11.75M.
E
Sell
3/14/2023Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 3/14/2023 due to a large decline in the growth index, solvency index and valuation index. Operating cash flow declined 23.73% from -$2.78M to -$3.44M, and EBIT declined 2.78% from -$5.75M to -$5.91M.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 3/14/2023 due to a large decline in the growth index, solvency index and valuation index. Operating cash flow declined 23.73% from -$2.78M to -$3.44M, and EBIT declined 2.78% from -$5.75M to -$5.91M.
D
Sell
2/9/2023Upgraded
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/30/2022Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to D from D+ on 11/30/2022 due to a significant decline in the valuation index and volatility index.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to D from D+ on 11/30/2022 due to a significant decline in the valuation index and volatility index.
D
Sell
11/15/2022Upgraded
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D+ from D on 11/15/2022 due to a substantial increase in the valuation index.
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D+ from D on 11/15/2022 due to a substantial increase in the valuation index.
D
Sell
10/27/2022Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to D from D+ on 10/27/2022 due to a substantial decline in the valuation index, total return index and volatility index.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to D from D+ on 10/27/2022 due to a substantial decline in the valuation index, total return index and volatility index.
D
Sell
10/5/2022Upgraded
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D+ from D on 10/5/2022 due to a significant increase in the valuation index and growth index. Operating cash flow increased 62.57% from -$9.37M to -$3.51M, earnings per share increased from -$0.0152 to -$0.01, and EBIT increased 32.94% from -$9.49M to -$6.36M.
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D+ from D on 10/5/2022 due to a significant increase in the valuation index and growth index. Operating cash flow increased 62.57% from -$9.37M to -$3.51M, earnings per share increased from -$0.0152 to -$0.01, and EBIT increased 32.94% from -$9.49M to -$6.36M.
D
Sell
5/16/2022Upgraded
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index.
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index.
E
Sell
5/13/2022Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
E
Sell
5/1/2022Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
D
Sell
11/9/2021Upgraded
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 17.1 to 16.05.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 17.1 to 16.05.
D
Sell
8/3/2020Downgrade
AVITA Therapeutics, Inc. (AVHHL) was downgraded to D from D+ on 8/3/2020 due to a decline in the valuation index.
AVITA Therapeutics, Inc. (AVHHL) was downgraded to D from D+ on 8/3/2020 due to a decline in the valuation index.
D
Sell
7/17/2020Upgraded
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D+ from D on 7/17/2020 due to an increase in the valuation index and growth index.
AVITA Therapeutics, Inc. (AVHHL) was upgraded to D+ from D on 7/17/2020 due to an increase in the valuation index and growth index.
D
Sell
2/19/2020Upgraded
Avita Medical Limited (AVMXF) was upgraded to D from D- on 2/19/2020 due to a significant increase in the total return index, solvency index and volatility index.
Avita Medical Limited (AVMXF) was upgraded to D from D- on 2/19/2020 due to a significant increase in the total return index, solvency index and volatility index.
D
Sell
11/3/2017None
AVITA Medical, Inc. (AVHHL) was downgraded to D- from U on 11/03/2017.
AVITA Medical, Inc. (AVHHL) was downgraded to D- from U on 11/03/2017.
OTC PK
03/24/2025 9:53AM Eastern
Quotes delayed
